Biomedicines · 2022
Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gupta Haripriya, Min Byeong-Hyun, Ganesan Raja, Gebru Yoseph Asmelash, Sharma Satya Priya, Park Eunju, Won Sung-Min, Jeong Jin-Ju, Lee Su-Been, Cha Min-Gi, Kwon Goo-Hyun, Jeong Min-Kyo, Hyun Ji-Ye, Eom Jung-A, Park Hee-Jin, Yoon Sang-Jun, Choi Mi-Ran, Kim Dong-Joon, Suk Ki-Tae
Аннотация
Non-alcoholic fatty liver disease (NAFLD) is considered to be a significant health threat globally, and has attracted growing concern in the research field of liver diseases. NAFLD comprises multifarious fatty degenerative disorders in the liver, including simple steatosis, steatohepatitis and fibrosis. The fundamental pathophysiology of NAFLD is complex and multifactor-driven. In addition to viruses, metabolic syndrome and alcohol, evidence has recently indicated that the microbiome is related to the development and progression of NAFLD. In this review, we summarize the possible microbiota-based therapeutic approaches and highlight the importance of establishing the diagnosis of NAFLD through the different spectra of the disease via the gut-liver axis.